Flerie FLERIE.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker FLERIE.ST. It has been listed since 11 October 2016. In the fiscal year to 31 December 2025, it reported revenue of SEK 8.8m and a net loss of SEK 756.9m. At that date it held total assets of SEK 3.40bn and shareholders' equity of SEK 3.38bn.

InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Thomas ElderedChairman of the BoardSEK 300,000
• Mr. Ted FjallmanChief Executive OfficerSEK 6.1m
• Ms. Cecilia von ScheeleDeputy Chief Executive Officer
• Mr. Mark QuickPartner
• Ms. Cecilia EdstromIndependent DirectorSEK 300,000
• Dr. Anders EkblomIndependent DirectorSEK 300,000
• Ms. Jenni NordborgIndependent DirectorSEK 300,000

Overall

20

Environment

23

Social

13

Governance

25

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.